Results for tag: "Corneal Endothelial Dystrophy Drug"

Corneal Endothelial Dystrophy (CED) is a group of rare, inherited eye disorders that affect the corneal endothelium, the innermost layer of the cornea. CED can cause vision loss due to corneal edema, or swelling, and can lead to corneal transplantation. Treatment for CED includes medications, such as topical corticosteroids, and surgical interventions, such as Descemet's Stripping Endothelial Keratoplasty (DSEK) and Descemet's Membrane Endothelial Keratoplasty (DMEK). The Optical Disorders Drugs market is a rapidly growing segment of the pharmaceutical industry, with a focus on the development of treatments for a variety of eye diseases. The Corneal Endothelial Dystrophy Drug market is a subset of this market, with a focus on the development of treatments for CED. Companies in this market are researching and developing new drugs and therapies to treat CED, as well as developing new surgical techniques to improve outcomes. Some companies in the Corneal Endothelial Dystrophy Drug market include Allergan, Bausch + Lomb, Novartis, Regeneron, and Santen Pharmaceuticals. Show Less Read more